Cochrane · systematic review · CD015078
Antiplatelet agents for the treatment of adults with COVID‐19
Fischer, A-L, Messer, S, Riera, R, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
11
No studies
3
Included studies
NR
No studies 3 · 21.4%Ungraded 0 · 0%Very low 2 · 14.3%Low 4 · 28.6%Moderate 5 · 35.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antiplatelets in hospitalised adults with moderate to severe COVID‐19
Population: hospitalised adults with COVID‐19 (moderate to severe disease)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
28‐day all‐cause mortality | RR 0.95 | 3 studies · 17249 participants | Moderate Downgraded: risk of bias |
Worsening up to day 28: participants with new need for invasive mechanical ventilation or death | RR 0.95 [0.9, 1.01] | 2 studies · 15266 participants | Moderate Downgraded: risk of bias |
Improvement up to day 28: participants discharged alive | RR 1 [0.96, 1.04] | 2 studies · 15454 participants | Moderate Downgraded: risk of bias |
Thrombotic events at longest | RR 0.9 [0.8, 1.02] | 4 studies · 17518 participants | Moderate Downgraded: risk of bias |
Serious adverse events at longest | Peto OR 1.57 [0.48, 5.14] | 1 study · 1815 participants | Low Downgraded: imprecision |
Adverse events during study treatment | no estimate extracted | NR | No studies |
Major bleeding events at longest | Peto OR 1.68 [1.29, 2.19] | 4 studies · 17527 participants | Moderate Downgraded: risk of bias |
Antiplatelets in non‐hospitalised adults with COVID‐19
Population: non‐hospitalised adults with mild COVID‐19
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at day 45 | Peto OR 1 [0.45, 2.22] | 2 studies · 4209 participants | Low Downgraded: imprecision |
Admission to hospital or death up to day 45 | Peto OR 0.79 [0.57, 1.1] | 2 studies · 4209 participants | Very low Downgraded: imprecision, indirectness |
Quality of life up to longest | no estimate extracted | NR | No studies |
Thrombotic events up to day 45 | Peto OR 0.37 [0.09, 1.46] | 2 studies · 4209 participants | Low Downgraded: imprecision |
Adverse events during study treatment | no estimate extracted | NR | No studies |
Serious adverse events up to day 45 | Peto OR 1 [0.6, 1.64] | 1 study · 3881 participants | Low Downgraded: imprecision |
Major bleeding events up to longest | no estimate extracted | 1 study · 328 participants | Very low Downgraded: imprecision |